Inhibition of ribonucleotide reductase by caracemide.
Caracemide, a new antitumor agent now in clinical trial, was tested against partially purified ribonucleotide reductase from rat Novikoff tumor. It was found to be an active inhibitor, about one-ninth as effective as hydroxyurea.
D000818:Animals; D000970:Antineoplastic Agents / Q000494:pharmacology*; D006918:Hydroxyurea / Q000031:analogs & derivatives* / Q000494:pharmacology; D066298:In Vitro Techniques; D009374:Neoplasms, Experimental / Q000201:enzymology; D051381:Rats; D012264:Ribonucleotide Reductases / Q000037:antagonists & inhibitors*
D000970:Antineoplastic Agents; D012264:Ribonucleotide Reductases; C044466:caracemide; D006918:Hydroxyurea